.

Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
AstraZeneca
UBS
Johnson and Johnson
Covington
McKinsey
Harvard Business School
US Army
Fuji
Dow

Generated: November 20, 2017

DrugPatentWatch Database Preview

Phentermine hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for phentermine hydrochloride and what is the scope of phentermine hydrochloride patent protection?

Phentermine hydrochloride
is the generic ingredient in eleven branded drugs marketed by Vitarine, Able, Usl Pharma, Sandoz Inc, Tg United Labs, Sandoz, Ken Lifescience, Mast Mm, Abc Holding, Teva, Invagen Pharms, Aurolife Pharma Llc, Lannett, Sun Pharm Inds, Camall, Elite Labs Inc, Ivax Pharms, Upsher-smith Labs, Solvay, Kvk Tech Inc, Watson Labs, Polygen Pharms, Ferndale Labs, Duramed Pharms Barr, Elite Labs, Ingenus Pharms Nj, Glaxosmithkline, Mikah Pharma, Lannett Holdings Inc, Zydus Pharms Usa Inc, Shire Richwood, Barr, Kvk Tech, Actavis Elizabeth, Prinston Inc, Tg United Inc, Citius Pharms, Sun Pharm Inds Inc, Avanthi Inc, and Vivus, and is included in one hundred NDAs. There are thirteen patents protecting this compound and two Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Phentermine hydrochloride has fourteen patent family members in ten countries.

There are seventeen drug master file entries for phentermine hydrochloride. Forty-seven suppliers are listed for this compound.

Pharmacology for phentermine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Ken Lifescience
PHENTERMINE HYDROCHLORIDE
phentermine hydrochloride
CAPSULE;ORAL205017-001Sep 25, 2014AARXNoNo► Subscribe► Subscribe► Subscribe
Vivus
QSYMIA
phentermine hydrochloride; topiramate
CAPSULE, EXTENDED RELEASE;ORAL022580-003Jul 17, 2012RXYesNo► Subscribe► SubscribeY ► Subscribe
Usl Pharma
PHENTERMINE HYDROCHLORIDE
phentermine hydrochloride
TABLET;ORAL088917-001Jul 17, 1985DISCNNoNo► Subscribe► Subscribe► Subscribe
Vivus
QSYMIA
phentermine hydrochloride; topiramate
CAPSULE, EXTENDED RELEASE;ORAL022580-002Jul 17, 2012RXYesNo► Subscribe► Subscribe ► Subscribe
Elite Labs
PHENTERMINE HYDROCHLORIDE
phentermine hydrochloride
CAPSULE;ORAL202248-001Sep 28, 2012AARXNoNo► Subscribe► Subscribe► Subscribe
Citius Pharms
SUPRENZA
phentermine hydrochloride
TABLET, ORALLY DISINTEGRATING;ORAL202088-001Jun 13, 2011DISCNNoNo► Subscribe► SubscribeY ► Subscribe
Sandoz Inc
PHENTERMINE HYDROCHLORIDE
phentermine hydrochloride
TABLET;ORAL088605-001Sep 28, 1987DISCNNoNo► Subscribe► Subscribe► Subscribe
Watson Labs
PHENTERMINE HYDROCHLORIDE
phentermine hydrochloride
TABLET;ORAL085739-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Mast Mm
ONA-MAST
phentermine hydrochloride
CAPSULE;ORAL086516-001Approved Prior to Jan 1, 1982DISCNNoNo► Subscribe► Subscribe► Subscribe
Vivus
QSYMIA
phentermine hydrochloride; topiramate
CAPSULE, EXTENDED RELEASE;ORAL022580-001Jul 17, 2012RXYesNo► Subscribe► SubscribeY ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: phentermine hydrochloride

Country Document Number Estimated Expiration
Denmark1001748► Subscribe
World Intellectual Property Organization (WIPO)2009098169► Subscribe
Germany69834255► Subscribe
European Patent Office2278590► Subscribe
Spain2263216► Subscribe
European Patent Office2254558► Subscribe
Portugal1001748► Subscribe
European Patent Office1001748► Subscribe
Japan2001510785► Subscribe
World Intellectual Property Organization (WIPO)9904758► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Cipla
Baxter
McKesson
Federal Trade Commission
Cerilliant
UBS
Daiichi Sankyo
Mallinckrodt
Chubb

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot